Table 1. Characteristics of studies included in the meta-analysis.
| Ref | Type of cancer | No. | Age, median (range) | Male/ Female | Stage | Follow up, months | PD-L1 (+/-) NO. | 3-year OS (+/-)% | 5-year OS (+/-)% |
|---|---|---|---|---|---|---|---|---|---|
| Boorjian, S. A et al.(2008)[22] | Urothelial cancer | 167 | NR | NR | I | > 120 | 27/140 | 53.2/82 | 41.2/68.6 |
| Chen, L., et al. (2014)[23] | Esophageal cancer | 99 | 59 | 76/23 | I-IV | NR | 82/17 | 40.4/63.6 | 22.2/63.6 |
| Chen, X. L et al.(2009)[12] | Pancreatic cancer | 40 | 54 (34–79) | 26/14 | I-IV | 58.5 | 18/22 | 9.2/57.4 | 0/16.8 |
| Chen, Y. B., et al. (2012)[24] | Lung cancer | 120 | NR | 90/30 | I-III | 27 | 69/51 | 4.3/47.1 | 0/29.6 |
| Cho, Y. A et al.(2011)[25] | Oral squamous cell carcinoma | 45 | NR | 32/13 | I-IV | NR | 26/19 | 49.9/63.1 | 45.3/63.1 |
| Gao, Q et al.(2009)[13] | Hepatocellular carcinoma | 240 | 52 (18–81) | 204/36 | I-III | 30 | 60/180 | 38.9/55 | 0/49 |
| Geng, Y., et al. (2014)[26] | Gastric cancer | 100 | 66.4 (30–87) | 61/39 | I-IV | >60 | 65/35 | 41.6/68.6 | 29.4/54.3 |
| Hamanishi, J et al.(2007)[27] | Ovarian cancer | 70 | 55 (26–78) | 0/70 | I-III | 62.3 | 48/22 | 78.6/90 | 48.8/80 |
| Hino, R et al.(2010)[5] | Melanoma | 59 | 69.4 (25–87) | 38/21 | I-IV | NR | 34/25 | 77.3/91.7 | 56.5/84.8 |
| Hou, J. et al.(2014)[28] | Gastric cancer | 111 | NR(18–96) | 75/36 | I-IV | 50 | 70/41 | 44.1/66.3 | NR |
| Karim, R et al.(2009)[29] | Cervical carcinoma | 115 | 48.5 (24–87) | NR | NR | 60 | 22/93 | 82.1/84.2 | 82.1/75.4 |
| Konishi, J et al.(2004)[8] | Lung cancer | 52 | 66.4 | 35/17 | I-IV | NR | 26/26 | NR | 59/48 |
| Liu, Y et al.(2013)[30] | Glioblastoma | 17 | NR (43–78) | 11/6 | NR | 60 | 6/11 | 0/27 | 0/13.3 |
| Loos, M et al.(2011)[31] | Esophageal cancer | 101 | 64 (33–83) | NR | I-IV | 75 | 37/64 | 52.7/83.5 | 32.8/69.5 |
| Mansfield, A. S., et al. (2014)[32] | Malignant mesotheliomas | 106 | NR | 90/16 | NR | NR | 42/64 | 2.1/10 | 0/4.8 |
| Mu, C. Y et al.(2011)[9] | Lung cancer | 109 | NR | NR | I-III | NR | 58/51 | 20.7/39.2 | NR |
| Nakanishi, J et al(2007)[33] | Urothelial cancer | 65 | NR | 47/18 | I-IV | NR | 46/19 | 68.8/100 | 68.8/100 |
| Ohigashi, Y et al.(2005)[34] | Esophageal cancer | 41 | 63 (46–73) | 32/9 | I-IV | 25 | 18/23 | 18/53.8 | 18/45.3 |
| Shi, S. J. et al.(2013)[7] | Colorectal cancer | 143 | NR | 61/82 | NR | 60 | 64/79 | 51.2/70.6 | 43.5/58.8 |
| Taube, J. M et al.(2012)[6] | Melanoma | 99 | 53 (7–94) | NR | NR | 100 | 43/56 | 84.2/62.5 | 84.2/62.5 |
| Ukpo, O. C et al.(2013)[35] | Oral squamous cell carcinoma | 181 | 55.8 | 158/23 | I-IV | 96 | 84/97 | 73.8/77.1 | 66.2/64.8 |
| Velcheti, V et al.(2014)-Greek cohort [11] | Lung cancer | 291 | NR | NR | I-IV | NR | 72/219 | 61.3/45.8 | 50.2/23.9 |
| Velcheti, V et al.(2014)-Yale University cohort [11] | Lung cancer | 153 | NR | NR | I-IV | NR | 55/98 | 71.5/45.3 | 53.3/36.8 |
| Wang, Y et al.(2009)[36] | Urothelial cancer | 50 | 61.7 (42–78) | 40/10 | NR | 27.94 | 36/14 | 63.4/98.5 | NR |
| Wu, C et al.(2006)[37] | Gastric cancer | 102 | 55 (28–77) | 75/27 | NR | 42 | 43/59 | 22.7/71 | 30.2/64.5 |
| Wu, K et al.(2009)[15] | Hepatocellular carcinoma | 71 | 48 (23–75) | 65/6 | I-IV | NR | 35/36 | 58.3/83.3 | 40.5/68.8 |
| Xylinas, E et al.(2014)[38] | Urothelial cancer | 96 | NR | NR | I-IV | NR | 24/72 | 66.7/69.4 | 62.5/69.4 |
| Yang, C. Y et al.(2014)[10] | Lung cancer | 163 | NR | 54/109 | I | 71 | 65/98 | 100/100 | 96.8/99 |
| Zhu, J., et al. (2014)[39] | Colorectal cancer | 101 | NR | 53/48 | NR | NR | 55/46 | NR | 61.8/80.4 |
NR: Not reported.